Atria Wealth Solutions, Inc. Galectin Therapeutics Inc Transaction History

Atria Wealth Solutions, Inc.

$8.79 Billion
Q2 2024

A detailed history of Atria Wealth Solutions, Inc. transactions in Galectin Therapeutics Inc stock. As of the latest transaction made, Atria Wealth Solutions, Inc. holds 213,800 shares of GALT stock, worth $570,846. This represents 0.01% of its overall portfolio holdings.

Number of Shares

213,800

Previous 214,800 0.47%

Holding current value

$570,846

Previous $513,000 5.85%

% of portfolio

0.01%

Previous 0.01%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 22, 2024	SELL	$2.13 - $4.2 $2,130 - $4,200	-1,000 Reduced 0.47%	213,800 $483,000
Q1 2024 May 13, 2024	SELL	$1.6 - $2.44 $56,000 - $85,400	-35,000 Reduced 14.01%	214,800 $513,000
Q4 2023 Feb 02, 2024	SELL	$1.6 - $2.18 $16,000 - $21,800	-10,000 Reduced 3.85%	249,800 $414,000
Q3 2023 Nov 08, 2023	SELL	$1.38 - $1.97 $1,380 - $1,970	-1,000 Reduced 0.38%	259,800 $498,000
Q2 2023 Aug 03, 2023	SELL	$1.32 - $2.08 $13,068 - $20,592	-9,900 Reduced 3.66%	260,800 $375,000
Q1 2023 Aug 22, 2023	BUY	$1.1 - $2.4 $2,750 - $6,000	2,500 Added 0.96%	263,300 $552,000
Q1 2023 Jun 14, 2023	BUY	$1.1 - $2.4 $8,140 - $17,760	7,400 Added 2.81%	270,700 $568,000
Q1 2023 May 10, 2023	SELL	$1.1 - $2.4 $8,140 - $17,760	-7,400 Reduced 2.73%	263,300 $552,000
Q4 2022 Aug 30, 2023	BUY	$1.03 - $1.66 $10,197 - $16,434	9,900 Added 3.8%	270,700 $305,000
Q4 2022 Feb 13, 2023	SELL	$1.03 - $1.66 $8,240 - $13,280	-8,000 Reduced 2.87%	270,700 $305,000
Q3 2022 Nov 14, 2022	SELL	$1.31 - $2.48 $3,930 - $7,440	-3,000 Reduced 1.06%	278,700 $454,000
Q2 2022 Aug 15, 2022	SELL	$1.19 - $1.74 $4,760 - $6,960	-4,000 Reduced 1.4%	281,700 $369,000
Q1 2022 May 16, 2022	BUY	$1.61 - $2.31 $459,977 - $659,967	285,700 New	285,700 $460,000

Others Institutions Holding GALT

# of Institutions

Shares Held

9.35M

Call Options Held

982K

Put Options Held

2.7K

View Full List

About GALECTIN THERAPEUTICS INC

Ticker GALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,426,000
Market Cap $159M
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...

More about GALT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Atria Wealth Solutions, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Atria Wealth Solutions, Inc. with notifications on news.

Account

Atria Wealth Solutions, Inc. Galectin Therapeutics Inc Transaction History